Revolutionizing Autism Therapy: Virtuix's Partnership with Sirica Therapeutics
Virtuix Holdings Inc. has partnered with Sirica Therapeutics to utilize its Omni One platform for autism therapy applications. The collaboration involves deploying two Omni One systems at Sirica's treatment center in the San Francisco Bay Area to provide movement-centered virtual reality and AI-assisted therapeutic experiences for children with autism and related disorders. Virtuix, a company with a market capitalization of $103 million, aims to expand into healthcare markets through this partnership.
Sirica Therapeutics plans to establish around 100 treatment centers across the United States, offering Cognitive Sensory Motor therapy that combines movement, sensory engagement, and cognitive challenge in treatment protocols. The partnership with Virtuix follows the company's research collaboration with Rutgers University on AI-assisted neurodivergent therapy and its work with Florida Gulf Coast University on neurological rehabilitation using the Omni One platform. Jan Goetgeluk, Founder and CEO of Virtuix, believes that AI-driven immersive simulation has the potential to revolutionize behavioral therapy delivery.
Virtuix's Omni One platform allows users to engage in various movements within virtual environments, expanding its applications beyond consumer entertainment into healthcare, defense, education, and enterprise sectors. The company's recent financial results for fiscal year 2026 showed revenue growth of 18% to $4.3 million, positive gross margin, and reduced operating expenses. Despite these improvements, Virtuix reported a net loss of $16.8 million for the year. Additionally, the company deployed its Omni One system to the Pennsylvania Air National Guard for evaluation in military training applications, aligning with the Air National Guard's exploration of virtual reality technology for movement-based simulations.
Investors can access comprehensive analysis of Virtuix Holdings Inc. through the Pro Research Report available on the platform, which offers insights into the company's financial performance and market valuation. The partnership with Sirica Therapeutics signifies Virtuix's commitment to expanding its presence in the healthcare sector and leveraging AI-driven technologies for therapeutic applications. Dr. Uli K. Chettipally, Founder and CEO of Sirica Therapeutics, aims to create a new model of care for autism and neurodiversity through the company's innovative therapy approach.
As Virtuix continues to explore new opportunities in healthcare and other sectors, investors are closely monitoring the company's performance and market developments. The collaboration with Sirica Therapeutics highlights the potential for AI-driven immersive simulation to enhance behavioral therapy delivery and improve outcomes for individuals with autism and related disorders. Virtuix's expansion into healthcare markets and strategic partnerships underscore its commitment to innovation and growth in the evolving landscape of therapeutic technologies.